Key Takeaways
- • Bill Ackman and wife Neri Oxman announced the creation of the Ackman Oxman Institute (AOI), a non-profit brain research and medical facility to be established in Manhattan, with an initial $400 million commitment in Pershing Square stock donations.
- • The Pershing Square Foundation has acquired a 400,000-square-foot biotech facility on West End Avenue in Manhattan, with an adjoining 130,000-square-foot building under contract and a vacant lot with air rights, totaling a planned 680,000-square-foot campus.
- • The institute will operate as a hybrid research and patient care center—not a pure academic institution—with planned focus areas including neuroscience, rehabilitation, brain-computer interfaces, medical-device development, hyperbaric oxygen treatments, and life-extension programs, with capability to develop and spin out commercial companies.
- • The initiative was catalyzed by daughter Lucy Ackman's serious brain hemorrhage in February 2026 and the subsequent rehabilitation care she received, though Ackman noted the concept had been under consideration for approximately five years, also inspired by Neri Oxman's mother, who died from Alzheimer's.
- • The institute plans to collaborate with multiple hospitals and medical schools rather than maintain an exclusive institutional relationship, with emphasis on accelerating the translation pathway from research to patient treatments and outcomes.
Summary
Bill Ackman announced on August 19, 2026, the formal establishment of the Ackman Oxman Institute, a non-profit dedicated to brain health research, rehabilitation, and human optimization. The initiative represents a significant philanthropic commitment, with Ackman and his wife Neri Oxman pledging approximately $400 million in Pershing Square stock to fund the operation. According to Dealroom.co, the institute emerged from deeply personal circumstances—specifically Lucy Ackman's serious brain hemorrhage in February 2026 and the medical care and rehabilitation she received thereafter—though Ackman indicated the concept had been under consideration for roughly five years, with additional inspiration drawn from Neri Oxman's mother, who died from Alzheimer's disease.
The Pershing Square Foundation has secured significant real estate to establish the institute's physical infrastructure. The organization acquired a vacant 400,000-square-foot biotech facility located on West End Avenue in Manhattan's Upper West Side. Additionally, an adjoining 130,000-square-foot building currently housing studio space is under contract, alongside a vacant lot with additional air rights. Combined, these properties are expected to create a 680,000-square-foot campus, positioning the institute as a substantial research and clinical hub.
The institute's operational model distinguishes itself from traditional academic medical centers by combining research with direct patient care. Planned scope encompasses neuroscience, neurorehabilitation, nutrition, brain-computer interfaces, medical-device development, human clinical trials, hyperbaric oxygen therapy, and life-extension programs. Critically, the AOI will retain commercial development capabilities—specifically the ability to develop, seed, and spin out companies from institutional research—rather than operate purely as a research-only entity. This structure reflects Ackman's stated goal of shortening the timeline from research conception to clinical treatment and measurable patient outcomes.
The institute will pursue a collaborative model with multiple hospitals and medical schools, avoiding exclusive institutional partnerships. This approach potentially positions the AOI as a flexible network hub rather than a vertically integrated medical system, allowing for broader knowledge-sharing and clinical reach. Ackman emphasized that the family intends to make learnings from Lucy's recovery and treatment available to the broader patient and research communities, framing the institute as a vehicle for translating personal experience into scalable medical infrastructure and innovation.
The Pershing Square Foundation has secured significant real estate to establish the institute's physical infrastructure. The organization acquired a vacant 400,000-square-foot biotech facility located on West End Avenue in Manhattan's Upper West Side. Additionally, an adjoining 130,000-square-foot building currently housing studio space is under contract, alongside a vacant lot with additional air rights. Combined, these properties are expected to create a 680,000-square-foot campus, positioning the institute as a substantial research and clinical hub.
The institute's operational model distinguishes itself from traditional academic medical centers by combining research with direct patient care. Planned scope encompasses neuroscience, neurorehabilitation, nutrition, brain-computer interfaces, medical-device development, human clinical trials, hyperbaric oxygen therapy, and life-extension programs. Critically, the AOI will retain commercial development capabilities—specifically the ability to develop, seed, and spin out companies from institutional research—rather than operate purely as a research-only entity. This structure reflects Ackman's stated goal of shortening the timeline from research conception to clinical treatment and measurable patient outcomes.
The institute will pursue a collaborative model with multiple hospitals and medical schools, avoiding exclusive institutional partnerships. This approach potentially positions the AOI as a flexible network hub rather than a vertically integrated medical system, allowing for broader knowledge-sharing and clinical reach. Ackman emphasized that the family intends to make learnings from Lucy's recovery and treatment available to the broader patient and research communities, framing the institute as a vehicle for translating personal experience into scalable medical infrastructure and innovation.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.